Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
How Has The Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market Growth Evolved From 2024 To 2025, And What’s Ahead?
There has been a robust expansion in the market size of ornithine transcarbamylase deficiency (otc deficiency) in recent times. It is projected to advance from a value of $0.83 billion in 2024 to $0.89 billion in 2025, with a compound annual growth rate (CAGR) of 6.9%. The surge witnessed during the historic period is due to heightened consciousness about rare metabolic disorders, advancements in genetic screening and diagnostics, enhancements in neonatal screening programs, an increase in the incidence of genetic testing in rare diseases, and betterment in neonatal screening programs.
The market for ornithine transcarbamylase deficiency (otc deficiency) is projected to experience vigorous expansion in the coming years, with its value expected to reach$1.15 billion by 2029″ at a compound annual growth rate (CAGR) of 6.8%. This predicted growth can be attributed to factors such as increased awareness and diagnosis, a growing number of urea cycle disorder cases, an increased emphasis on treating rare diseases, rising research and clinical trials, and better patient access to treatments. Expected trends for this forecast period include advancements in gene therapies and gene editing technologies, the emergence of enzyme replacement therapies, cooperative research ventures and partnerships, advancements in diagnostic technology, and increased government funding and incentives for orphan drugs.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=22084&type=smp
What Are the Core Market Drivers Propelling Growth in the Ornithine Transcarbamylase Deficiency (OTC Deficiency) Industry?
Higher demand for gene therapies is projected to boost the ornithine transcarbamylase deficiency market’s expansion. Gene therapy is a medical procedure that involves modifying a person’s genetic matter to prevent or treat diseases. This increasing demand is due to the higher occurrence of genetic illnesses, as there are generally limited treatments for such conditions, making gene therapy a potential solution to target the fundamental causes instead of just dealing with symptoms. Ornithine transcarbamylase deficiency reveals the potential of gene therapies by amending the genetic anomaly that interrupts the urea cycle. This enables targeted treatments to restore metabolic function, thereby avoiding harmful ammonia accumulation. For example, the American Society of Gene & Cell Therapy reported in January 2024 that the quantity of gene therapies in Phase III rose by 10% from the last quarter in Q4 2023, representing the first increase since Q3 2022. Consequently, the escalating demand for gene therapies is propelling the growth of the ornithine transcarbamylase deficiency market.
How Is the Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market Segmented?
The ornithine transcarbamylase deficiency (otc deficiency)market covered in this report is segmented –
1) By Product Type: DTX-301; SEL-313; SHP-641; PRX-OTC
2) By Treatment Type: Gene Therapy; Liver Transplant; Dietary Management; Other Treatement Type
3) By Diagnosis: Genetic Testing; Ammonia Level Testing
4) By End-User: Hospitals; Specialty Clinics; Research Institutes; Other End Users
Subsegments:
1) By DTX-301: Adeno-Associated Virus (AAV)-Based Gene Therapy; Intravenous Dosing Formulation
2) By SEL-313: Immune Tolerance-Inducing Therapy; Enzyme Replacement Therapy (ERT) Combination
3) By SHP-641: Small Molecule Therapy; mRNA-Based Therapeutic Approach
4) By PRX-OTC: Recombinant Enzyme Replacement Therapy; Protein Engineering-Based Therapy
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=22084&type=smp
Which Regions Are Driving the Next Phase of the Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market Growth?
North America was the largest region in the ornithine transcarbamylase deficiency (OTC Deficiency) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the ornithine transcarbamylase deficiency (OTC deficiency) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Key Market Trends and Innovations Are Shaping the Future of the Ornithine Transcarbamylase Deficiency (OTC Deficiency) Industry?
Leading firms in the ornithine transcarbamylase deficiency (OTC Deficiency) market are centered on innovating therapy solutions, with a particular emphasis on mRNA therapeutics, to improve treatment effectiveness and address the root genetic origin of OTC deficiency. mRNA therapeutics are a new grade of pharmaceutical treatments that employ messenger RNA molecules to guide cells into producing specific proteins for medicinal use. These treatments harness the body’s inherent protein synthesis system to tackle ailments ranging from genetic defects, infectious diseases, to cancers. For example, Arcturus Therapeutics Holdings Inc., an American biotechnology enterprise, was granted Fast Track Designation by the U.S. Food and Drug Administration (FDA) for its mRNA therapeutic candidate for OTC deficiency, ARCT-810, back in June 2023. This special status aims to expedite the development and evaluation process of the drug, resulting in potential advantages such as more frequent interactions with the FDA and priority examination. ARCT-810 intends to aid patients suffering from OTC deficiency, a urea cycle disorder, by enabling the production of a functional OTC enzyme within their liver cells. Ultimately, this goes toward tackling the root cause of the disorder and potentially enhancing the patients’ quality of life.
View the full report here:
How Is the Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market Defined and What Are Its Core Parameters?
Ornithine transcarbamylase (OTC) deficiency refers to a rare genetic disorder caused by mutations in the OTC gene, leading to a deficiency of the ornithine transcarbamylase enzyme, which is essential for the urea cycle to remove ammonia from the body. The condition results in hyperammonemia, causing symptoms such as vomiting, lethargy, seizures, and coma in severe cases, particularly in newborns.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=22084
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
